Anaveon
Bottmingen
About Anaveon
Anaveon are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $154.7M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2021)
- Website: anaveon.com
- Phone: [email protected]
Industries & Categories
Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/anaveon-27373 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.